FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W1503992685> ?p ?o ?g. }

• W1503992685 abstract "Based on recent clinical success of tumor immunotherapies that block immune suppressive mechanisms to restore T cell function, there is a profound interest in the clinical development of T cell targeted therapies. We have produced a trastuzumab-based HER2 T cell dependent bispecific antibody (HER2-TDB) that conditionally activates T cells resulting in lysis of HER2 expressing cancer cells at low picomolar concentrations. Due to its unique mechanism of action, which is unrelated to HER2 signaling or sensitivity to chemotherapeutic agents, HER2-TDB can eliminate cells refractory to currently approved HER2 therapies. The potent anti-tumor activity of HER2-TDB was demonstrated using four model systems including MMTV-huHER2 and huCD3 transgenic mice. We demonstrate inhibitory effect of PD-L1 expression on the activity of bispecific T cell recruiting antibodies. This resistance mechanism is reversed by anti-PD-L1 treatment and combination of HER2-TDB with anti-PD-L1 immune therapy resulted in enhanced inhibition of tumor growth, increased response rates and durable responses. Significance: This report presents a new immunotherapy for HER2+ breast cancer with an alternative, extremely potent mechanism of action that is effective in cells resistant to current HER2 targeted therapies. Several significant advances are provided to bispecific T cell recruiting antibodies: we characterize a critical resistance mechanism, a potential diagnostic marker, a novel transgenic efficacy model and significantly improve the drug-like properties by using technology based on full length antibodies with natural architecture. Finally we demonstrate the benefit of combining two immune therapies: direct polyclonal recruitment of T cell activity together with inhibiting the T cell suppressive PD-1/PD-L1 signaling results in enhanced and durable long term responses. Citation Format: Teemu T Junttila, Ji Li, Jennifer Johnston, Maria Hristopoulos, Robyn Clark, Diego Ellerman, Bu-Er Wang, Yijin Li, Mary Mathieu, Guangmin Li, Judy Young, Elizabeth Luis, Gail Lewis Phillips, Eric Stefanich, Cristoph Spiess, Andrew Polson, Bryan Irving, Justin M Scheer, Melissa R Junttila, Mark S Dennis, Robert Kelley, Klara Totpal, Allen Ebens. HER2 T cell dependent bispecific antibody (HER2-TDB) for treatment of HER2 positive breast cancer [abstract]. In: Proceedings of the Thirty-Seventh Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2014 Dec 9-13; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2015;75(9 Suppl):Abstract nr S1-07." @default.
• W1503992685 created "2016-06-24" @default.
• W1503992685 creator A5002138594 @default.
• W1503992685 creator A5004730502 @default.
• W1503992685 creator A5006675915 @default.
• W1503992685 creator A5009606169 @default.
• W1503992685 creator A5014350878 @default.
• W1503992685 creator A5015305870 @default.
• W1503992685 creator A5022150086 @default.
• W1503992685 creator A5022734195 @default.
• W1503992685 creator A5023502262 @default.
• W1503992685 creator A5023967455 @default.
• W1503992685 creator A5030418854 @default.
• W1503992685 creator A5038648623 @default.
• W1503992685 creator A5040110214 @default.
• W1503992685 creator A5042302638 @default.
• W1503992685 creator A5052002077 @default.
• W1503992685 creator A5064803348 @default.
• W1503992685 creator A5066511649 @default.
• W1503992685 creator A5067027064 @default.
• W1503992685 creator A5069254746 @default.
• W1503992685 creator A5072076025 @default.
• W1503992685 creator A5073515105 @default.
• W1503992685 creator A5076253271 @default.
• W1503992685 creator A5088134239 @default.
• W1503992685 date "2015-04-30" @default.
• W1503992685 modified "2023-09-26" @default.
• W1503992685 title "Abstract S1-07: HER2 T cell dependent bispecific antibody (HER2-TDB) for treatment of HER2 positive breast cancer" @default.
• W1503992685 doi "https://doi.org/10.1158/1538-7445.sabcs14-s1-07" @default.
• W1503992685 hasPublicationYear "2015" @default.
• W1503992685 type Work @default.
• W1503992685 sameAs 1503992685 @default.
• W1503992685 citedByCount "0" @default.
• W1503992685 crossrefType "proceedings-article" @default.
• W1503992685 hasAuthorship W1503992685A5002138594 @default.
• W1503992685 hasAuthorship W1503992685A5004730502 @default.
• W1503992685 hasAuthorship W1503992685A5006675915 @default.
• W1503992685 hasAuthorship W1503992685A5009606169 @default.
• W1503992685 hasAuthorship W1503992685A5014350878 @default.
• W1503992685 hasAuthorship W1503992685A5015305870 @default.
• W1503992685 hasAuthorship W1503992685A5022150086 @default.
• W1503992685 hasAuthorship W1503992685A5022734195 @default.
• W1503992685 hasAuthorship W1503992685A5023502262 @default.
• W1503992685 hasAuthorship W1503992685A5023967455 @default.
• W1503992685 hasAuthorship W1503992685A5030418854 @default.
• W1503992685 hasAuthorship W1503992685A5038648623 @default.
• W1503992685 hasAuthorship W1503992685A5040110214 @default.
• W1503992685 hasAuthorship W1503992685A5042302638 @default.
• W1503992685 hasAuthorship W1503992685A5052002077 @default.
• W1503992685 hasAuthorship W1503992685A5064803348 @default.
• W1503992685 hasAuthorship W1503992685A5066511649 @default.
• W1503992685 hasAuthorship W1503992685A5067027064 @default.
• W1503992685 hasAuthorship W1503992685A5069254746 @default.
• W1503992685 hasAuthorship W1503992685A5072076025 @default.
• W1503992685 hasAuthorship W1503992685A5073515105 @default.
• W1503992685 hasAuthorship W1503992685A5076253271 @default.
• W1503992685 hasAuthorship W1503992685A5088134239 @default.
• W1503992685 hasConcept C121608353 @default.
• W1503992685 hasConcept C126322002 @default.
• W1503992685 hasConcept C159654299 @default.
• W1503992685 hasConcept C203014093 @default.
• W1503992685 hasConcept C2775930923 @default.
• W1503992685 hasConcept C2776090121 @default.
• W1503992685 hasConcept C2777701055 @default.
• W1503992685 hasConcept C2779786085 @default.
• W1503992685 hasConcept C2780674031 @default.
• W1503992685 hasConcept C3020495827 @default.
• W1503992685 hasConcept C502942594 @default.
• W1503992685 hasConcept C530470458 @default.
• W1503992685 hasConcept C542903549 @default.
• W1503992685 hasConcept C71924100 @default.
• W1503992685 hasConcept C8891405 @default.
• W1503992685 hasConcept C96232424 @default.
• W1503992685 hasConcept C98274493 @default.
• W1503992685 hasConceptScore W1503992685C121608353 @default.
• W1503992685 hasConceptScore W1503992685C126322002 @default.
• W1503992685 hasConceptScore W1503992685C159654299 @default.
• W1503992685 hasConceptScore W1503992685C203014093 @default.
• W1503992685 hasConceptScore W1503992685C2775930923 @default.
• W1503992685 hasConceptScore W1503992685C2776090121 @default.
• W1503992685 hasConceptScore W1503992685C2777701055 @default.
• W1503992685 hasConceptScore W1503992685C2779786085 @default.
• W1503992685 hasConceptScore W1503992685C2780674031 @default.
• W1503992685 hasConceptScore W1503992685C3020495827 @default.
• W1503992685 hasConceptScore W1503992685C502942594 @default.
• W1503992685 hasConceptScore W1503992685C530470458 @default.
• W1503992685 hasConceptScore W1503992685C542903549 @default.
• W1503992685 hasConceptScore W1503992685C71924100 @default.
• W1503992685 hasConceptScore W1503992685C8891405 @default.
• W1503992685 hasConceptScore W1503992685C96232424 @default.
• W1503992685 hasConceptScore W1503992685C98274493 @default.
• W1503992685 hasLocation W15039926851 @default.
• W1503992685 hasOpenAccess W1503992685 @default.
• W1503992685 hasPrimaryLocation W15039926851 @default.
• W1503992685 hasRelatedWork W11055546 @default.
• W1503992685 hasRelatedWork W1269684 @default.
• W1503992685 hasRelatedWork W17404775 @default.
• W1503992685 hasRelatedWork W19818330 @default.
• W1503992685 hasRelatedWork W2151330 @default.
• W1503992685 hasRelatedWork W6417289 @default.

• next